• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Mayo Clinic Launches CQI Program to Minimize Complications from Retained Blood in Heart Surgery Patients

by HITC Staff 05/11/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Mayo Clinic Launches CQI Program to Minimize Complications from Retained Blood in Heart Surgery Patients

ClearFlow, a California-based company that develops technology to maximize post-operative blood evacuation after cardiac surgery and Mayo Clinic are launching research a Continuous Quality Improvement (CQI) program for patients recovering from heart surgery. Simon Maltais, MD, PhD, Mayo Clinic Associate Professor of Surgery, Division of Cardiovascular Surgery will serve as the Principal Investigator for the CQI program. 

Recent studies have demonstrated that up to 20% of patients recovering from heart surgery have some form of intervention due to retained blood that can slow recovery and increase the costs of care,” said Edward Boyle, MD, co-founder and Chairman of ClearFlow. “The goal of this study is to implement structured protocols in the ICU that can facilitate improved recovery for patients after heart surgery. These protocols will include use of PleuraFlow® Active Clearance Technology® (ACT®) System, a simple bedside device used to keep chest tubes free from clogging during the first 24–48 hours of recovery after heart surgery.”

An award-winning innovation developed by cardiothoracic surgeons, PleuraFlow ACT has been shown to reduce both Retained Blood Syndrome (RBS) and post-operative atrial fibrillation in published studies. A key aim of this study is to develop structured ICU protocols to minimize the potential for retained blood within the framework of a continuous quality improvement program and measure patient outcomes improvement.

A recent study by independent investigators in Germany, published in the Journal of Thoracic and Cardiovascular Surgery, affirmed a reduction in retained blood interventions required after surgery from 20% to 11% (43% reduction) in all cardiac surgery patients when the PleuraFlow System was used, as well as a reduction in Postoperative Atrial Fibrillation (POAF) from 30% to 20% (a 33% reduction) in propensity matched patients. The study results demonstrate that by implementing a quality improvement protocol to reduce chest tube clogging, complications can be reduced and patient outcomes can be improved. The cost to treat these complications add an enormous burden to the healthcare system.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: ClearFlow, Mayo Clinic

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |